Literature DB >> 32769047

LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women.

Lancia N F Darville1, Jayden K Cline2, Carrie Rozmeski2, Yessica C Martinez2, Shannan Rich3, Steven A Eschrich2, Kathleen M Egan4, Lusine Yaghjyan3, John M Koomen2.   

Abstract

In order to undertake an epidemiologic study relating levels of parent estrogens (estrone and estradiol) and estrogen metabolites (EMs) to other breast cancer risk factors, we have optimized methods for EM quantification with ultra high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). A two-step approach was adopted; the first step comprised method development and evaluation of the method performance. The second step consisted of applying this method to quantify estrogens in postmenopausal women and determine if the observed patterns are consistent with the existing literature and prior knowledge of estrogen metabolism. First, 1-methylimidazole-2-sulfonyl chloride (MIS) was used to derivatize endogenous estrogens and estrogen metabolites in urine from study participants. Since C18 reversed phase columns have not been able to separate all the structurally related EMs, we used a C18-pentafluorophenyl (PFP) column. The parent estrogens and EMs were baseline resolved with distinct retention times on this C18-PFP column using a 30 min gradient. This method was used to quantify the parent estrogens and 13 EMs in urine samples collected in an initial pilot study involving males as well as pre- and peri-menopausal females to assess a range of EM levels in urine samples and enable comparison to the previous literature for assay evaluation. Detection limits ranged from 1 - 20 pg/mL depending on the EM. We evaluated matrix effects and interference as well as the intra- and inter-batch reproducibility including hydrolysis, extraction, derivatization and LC-MS analysis using charcoal-stripped human urine as a matrix. Methods were then applied to the measurement of estrogens in urine samples from 169 postmenopausal women enrolled in an epidemiological study to examine relationships between breast cancer risk, the intestinal microbiome, and urinary EMs. The results from our cohort are comparable to previous reports on urinary EMs in postmenopausal women and enabled thorough evaluation of the method.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Derivatization; Estrogens; Liquid chromatography-high resolution mass spectrometry; Metabolites

Mesh:

Substances:

Year:  2020        PMID: 32769047      PMCID: PMC7882395          DOI: 10.1016/j.jchromb.2020.122288

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  37 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

Review 2.  Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.

Authors:  Qingqing Wang; Lisa Bottalico; Clementina Mesaros; Ian A Blair
Journal:  Steroids       Date:  2014-08-20       Impact factor: 2.668

3.  Urinary estrogen metabolites and breast cancer: a case-control study.

Authors:  G C Kabat; C J Chang; J A Sparano; D W Sepkovie; X P Hu; A Khalil; R Rosenblatt; H L Bradlow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-07       Impact factor: 4.254

Review 4.  Estrogen metabolism and breast cancer.

Authors:  Hamed Samavat; Mindy S Kurzer
Journal:  Cancer Lett       Date:  2014-04-28       Impact factor: 8.679

Review 5.  From Pregnancy to Preeclampsia: A Key Role for Estrogens.

Authors:  Nadia Berkane; Philippe Liere; Jean-Paul Oudinet; Alexandre Hertig; Guillaume Lefèvre; Nicola Pluchino; Michael Schumacher; Nathalie Chabbert-Buffet
Journal:  Endocr Rev       Date:  2017-04-01       Impact factor: 19.871

6.  Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer.

Authors:  Francesmary Modugno; Kevin E Kip; Barbara Cochrane; Lewis Kuller; Thomas L Klug; Thomas E Rohan; Rowan T Chlebowski; Norman Lasser; Marcia L Stefanick
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

Review 7.  Urinary 2/16 estrogen metabolite ratio levels in healthy women: a review of the literature.

Authors:  Cher Dallal; Emanuela Taioli
Journal:  Mutat Res       Date:  2010-07-01       Impact factor: 2.433

Review 8.  Estrogen hydroxylation--the good and the bad.

Authors:  Daniel W Sepkovic; H Leon Bradlow
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

9.  Urinary estrogen levels in women on contraceptives in enugu, South-East Nigeria.

Authors:  Ignatius C Maduka; Francis E Ezeonu; Emeka E Neboh; Elvis N Shu; Ebele J Ikekpeazu
Journal:  J Family Med Prim Care       Date:  2012-01

10.  Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.

Authors:  Roni T Falk; Louise A Brinton; Joanne F Dorgan; Barbara J Fuhrman; Timothy D Veenstra; Xia Xu; Gretchen L Gierach
Journal:  Breast Cancer Res       Date:  2013-04-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.